Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2025

May 29, 2025

30610_dirs_2025-05-29_6de788b7-6ba4-4ecb-a15c-e985075e92e5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-05-27

Reporting Person: Mock James M (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-27 Common Stock M 773 Acquired 16396 Direct
2025-05-27 Common Stock F 374 $26.26 Disposed 16022 Direct
2025-05-28 Common Stock M 328 Acquired 16350 Direct
2025-05-28 Common Stock F 159 $26.76 Disposed 16191 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-05-27 Restricted Stock Units $ M 773 Disposed Common Stock (773) Direct
2025-05-28 Restricted Stock Units $ M 328 Disposed Common Stock (328) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

F3: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F4: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.